Company news

SAB Biotherapeutics, Inc. news in 2022

SAB Biotherapeutics, Inc.'s news releases, calls and decks from 2022, newest first.

View company

SAB Biotherapeutics Announces $7.9 Million Private Placement of Common Stock

December 6, 2022

SAB Biotherapeutics Initiates IND-Enabling GLP Toxicology Study for SAB-142, Novel Immunotherapeutic for Type 1 Diabetes

November 20, 2022

SAB Biotherapeutics Provides Company Update for Q3 2022 Financial Results

November 14, 2022

SAB Biotherapeutics Announces Exclusive Manufacturing Partnership with Emergent BioSolutions

October 26, 2022

SAB Biotherapeutics Unveils New Data at ISIRV OPTIONS XI Conference Validating SAB-176 Proof of Concept in Reducing Viral Load and Improving Symptoms of Influenza and Showing SAB-185 Effective Against Multiple COVID-19 Variants Including Omicron

September 27, 2022

SAB Biotherapeutics to Present New Data at ISIRV OPTIONS XI Conference on SAB-176 Phase 2a Influenza Trial and SAB-185’s Effectiveness Against Multiple COVID-19 Variants

September 22, 2022

SAB Biotherapeutics Provides Company Update for Q2 2022 Financial Results

August 9, 2022

SAB Biotherapeutics Advancing Pipeline and Expands into Treatment for C. Diff. as DoD Contract Winds Down

August 8, 2022

SAB Biotherapeutics Announces Election of Rear Admiral (retired) Scott Giberson, RPh, MPH, D.Sc., to Board of Directors

July 10, 2022

SAB Biotherapeutics Announces Appointment of Alexandra Kropotova, M.D., as Chief Medical Officer

June 5, 2022

SAB Biotherapeutics Provides Company Update for Q1 2022 Financial Results

May 11, 2022

SAB Biotherapeutics Appoints Mark J. Ratain, MD, to the Company’s Board of Scientific Advisors

April 4, 2022

SAB Biotherapeutics Provides Company Update and Reports Full Year 2021 Financial Results

March 28, 2022

SAB Biotherapeutics Reports NIH is Discontinuing Phase 3 ACTIV-2 Trial Assessing SAB-185 for Treatment of COVID-19 Due to Declining COVID Hospitalizations

March 1, 2022

SAB Biotherapeutics Announces Publication of Nonclinical Data Demonstrating SAB-185 Has High Potency for Effectively Neutralizing Circulating and Emerging SARS-CoV-2 Variants

February 28, 2022

SAB Biotherapeutics Announces Update to the Phase 3 NIH ACTIV-2 Trial Design Evaluating SAB-185 for Treatment of COVID-19

February 24, 2022

SAB Biotherapeutics Reports Positive Phase 2 Virology Data Demonstrating SAB-185 Met Criteria for Advancement to Phase 3 in NIH ACTIV-2 Trial for Treatment of COVID-19

January 23, 2022

Decks in 2022